Strides Shasun to divest API arm to Solara for Rs 131 cr

Press Trust of India  |  New Delhi 

Drug firm today said its board has approved a proposal to divest its entire shareholding in to Mumbai-based Active Pharma Sciences for Rs 131 crore.

The company's board today approved divestment of its 100 per cent shareholding in to Solara, said in a regulatory filing.

The divestment will help Strides become leaner, while retaining supply chain security for the formulations portfolio, said in a regulatory filing.

"Under the proposed terms of the agreement Strides will divest 100 per cent of the issued capital in to for a cash consideration of Rs 1,310 million, as determined by independent valuers," it said.

The transaction is subject to customary closing conditions including approval by the shareholders of both the companies, it added.

As per the deal, Strides through its long term development and with will get a 'most favoured customer' status for all the drug master files (DMFs) required for the integrated formulations portfolio.

Shares of the today ended 0.18 per cent down at Rs 645.75 on BSE.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, April 24 2018. 16:20 IST